The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase Ia, first-in-human study of AbGn-107, a novel antibody-drug conjugate (ADC), in patients with gastric, colorectal, pancreatic, or biliary cancers.
 
Andrew H. Ko
Honoraria - Biomedical Learning Institute; Biomedical Learning Institute; Biomedical Learning Institute; Biomedical Learning Institute; Clinical Care Options; Clinical Care Options; Clinical Care Options; Clinical Care Options; Dava Oncology; Dava Oncology; Dava Oncology; Dava Oncology; Elsevier; Elsevier; Elsevier; Elsevier; MORE Health; MORE Health; MORE Health; MORE Health; OncLive; OncLive; OncLive; OncLive; Peerview; Peerview; Peerview; Peerview; Pharmatecture; Pharmatecture; Pharmatecture; Pharmatecture; Research to Practice; Research to Practice; Research to Practice; Research to Practice; Xcenda; Xcenda; Xcenda; Xcenda
Consulting or Advisory Role - ARMO Biosciences; ARMO Biosciences; ARMO Biosciences; ARMO Biosciences; AstraZeneca; AstraZeneca; AstraZeneca; AstraZeneca; Celgene; Celgene; Celgene; Celgene; ERYTECH Pharma; ERYTECH Pharma; ERYTECH Pharma; ERYTECH Pharma; Gilead Sciences; Gilead Sciences; Gilead Sciences; Gilead Sciences; Gritstone Bio; Gritstone Bio; Gritstone Bio; Gritstone Bio; Imugene; Imugene; Imugene; Imugene; Pharmacyclics; Pharmacyclics; Pharmacyclics; Pharmacyclics; Rafael Pharmaceuticals; Rafael Pharmaceuticals; Rafael Pharmaceuticals; Rafael Pharmaceuticals; SynCoreBio; SynCoreBio; SynCoreBio; SynCoreBio; Vicus Therapeutics; Vicus Therapeutics; Vicus Therapeutics; Vicus Therapeutics
Speakers' Bureau - Clinical Care Options; Clinical Care Options; Clinical Care Options; Clinical Care Options
Research Funding - AbGenomics International (Inst); AbGenomics International (Inst); AbGenomics International (Inst); AbGenomics International (Inst); Apexigen (Inst); Apexigen (Inst); Apexigen (Inst); Apexigen (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Celgene (Inst); Celgene (Inst); Celgene (Inst); Genentech/Roche (Inst); Genentech/Roche (Inst); Genentech/Roche (Inst); Genentech/Roche (Inst); Halozyme (Inst); Halozyme (Inst); Halozyme (Inst); Halozyme (Inst); Merck (Inst); Merck (Inst); Merck (Inst); Merck (Inst); Merrimack (Inst); Merrimack (Inst); Merrimack (Inst); Merrimack (Inst); TwoPoreGuys/Ontera (Inst); TwoPoreGuys/Ontera (Inst); TwoPoreGuys/Ontera (Inst); TwoPoreGuys/Ontera (Inst)
 
Andrew L. Coveler
Consulting or Advisory Role - Abbvie; Abbvie; Abbvie; Abbvie; Halozyme; Halozyme; Halozyme; Halozyme; Merrimack; Merrimack; Merrimack; Merrimack; Seagen; Seagen; Seagen; Seagen
Research Funding - AbGenomics International (Inst); AbGenomics International (Inst); AbGenomics International (Inst); AbGenomics International (Inst); Amgen (Inst); Amgen (Inst); Amgen (Inst); Amgen (Inst); Amgen (Inst); Amgen (Inst); Amgen (Inst); Amgen (Inst); Genentech (Inst); Genentech (Inst); Genentech (Inst); Genentech (Inst); Gilead Sciences (Inst); Gilead Sciences (Inst); Gilead Sciences (Inst); Gilead Sciences (Inst); Halozyme (Inst); Halozyme (Inst); Halozyme (Inst); Halozyme (Inst); Immunomedics (Inst); Immunomedics (Inst); Immunomedics (Inst); Immunomedics (Inst); Lilly (Inst); Lilly (Inst); Lilly (Inst); Lilly (Inst); MedImmune (Inst); MedImmune (Inst); MedImmune (Inst); MedImmune (Inst); Newlink Genetics (Inst); Newlink Genetics (Inst); Newlink Genetics (Inst); Newlink Genetics (Inst); Novocure (Inst); Novocure (Inst); Novocure (Inst); Novocure (Inst); Onconova Therapeutics (Inst); Onconova Therapeutics (Inst); Onconova Therapeutics (Inst); Onconova Therapeutics (Inst); Seagen (Inst); Seagen (Inst); Seagen (Inst); Seagen (Inst); Taiho Pharmaceutical (Inst); Taiho Pharmaceutical (Inst); Taiho Pharmaceutical (Inst); Taiho Pharmaceutical (Inst); XBiotech (Inst); XBiotech (Inst); XBiotech (Inst); XBiotech (Inst)
Travel, Accommodations, Expenses - Abbvie; Abbvie; Abbvie; Abbvie; Halozyme; Halozyme; Halozyme; Halozyme
 
Benjamin L. Schlechter
No Relationships to Disclose
 
Tanios S. Bekaii-Saab
Consulting or Advisory Role - Abbvie; Abbvie; Abbvie; Abbvie; Amgen; Amgen; Amgen; Amgen; Amgen (Inst); Amgen (Inst); AstraZeneca; AstraZeneca; AstraZeneca; AstraZeneca; Bayer; Bayer; Bayer; Bayer; Bayer (Inst); Bayer (Inst); Bayer (Inst); Bayer (Inst); Boehringer Ingelheim; Boehringer Ingelheim; Boehringer Ingelheim; Boehringer Ingelheim; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Celgene; Celgene; Celgene; Celgene; Celgene (Inst); Celgene (Inst); Celgene (Inst); Celgene (Inst); Genentech/Roche; Genentech/Roche; Genentech/Roche; Genentech/Roche; Immuneering; Immuneering; Immuneering; Immuneering; Imugene; Imugene; Imugene; Imugene; Incyte (Inst); Incyte (Inst); Incyte (Inst); Incyte (Inst); Ipsen (Inst); Ipsen (Inst); Ipsen (Inst); Ipsen (Inst); Lilly; Lilly; Lilly; Lilly; Lilly (Inst); Lilly (Inst); Lilly (Inst); Lilly (Inst); NCCN; NCCN; NCCN; NCCN; Pfizer; Pfizer; Pfizer; Pfizer; Pfizer (Inst); Pfizer (Inst); Pfizer (Inst); Pfizer (Inst); Regeneron; Regeneron; Regeneron; Regeneron; Roche/Genentech (Inst); Roche/Genentech (Inst); Roche/Genentech (Inst); Roche/Genentech (Inst); Seagen (Inst); Seagen (Inst); Seagen (Inst); Seagen (Inst); Sirtex Medical; Sirtex Medical; Sirtex Medical; Sirtex Medical; Taiho Pharmaceutical; Taiho Pharmaceutical; Taiho Pharmaceutical; Taiho Pharmaceutical
Research Funding - NCCN; NCCN; NCCN; NCCN; NCI; NCI; NCI; NCI; Oncolytics; Oncolytics; Oncolytics; Oncolytics
Other Relationship - ARMO BioSciences; ARMO BioSciences; ARMO BioSciences; ARMO BioSciences; AstraZeneca; AstraZeneca; AstraZeneca; AstraZeneca; Exelixis; Exelixis; Exelixis; Exelixis; Merck (Inst); Merck (Inst); Merck (Inst); Merck (Inst); Polaris; Polaris; Polaris; Polaris; Sillajen; Sillajen; Sillajen; Sillajen
 
Brian M. Wolpin
Honoraria - Celgene; Celgene; Celgene; Celgene; G1 Therapeutics; G1 Therapeutics; G1 Therapeutics; G1 Therapeutics
Consulting or Advisory Role - BioLineRx; BioLineRx; BioLineRx; BioLineRx; Celgene; Celgene; Celgene; Celgene; G1 Therapeutics; G1 Therapeutics; G1 Therapeutics; G1 Therapeutics; Genentech; Genentech; Genentech; Genentech; GRAIL; GRAIL; GRAIL; GRAIL; GRAIL; GRAIL; GRAIL; GRAIL
Research Funding - Celgene; Celgene; Celgene; Celgene; Lilly; Lilly; Lilly; Lilly
 
Jeffrey William Clark
Consulting or Advisory Role - Emas pharma; Emas pharma; Emas pharma; Emas pharma
Research Funding - Pfizer (Inst); Pfizer (Inst); Pfizer (Inst); Pfizer (Inst)
 
Yi-Lin Cheng
Employment - AbGenomics International; AbGenomics International; AbGenomics International; AbGenomics International
 
Ting-Ying Cheng
Employment - AbGenomics International; AbGenomics International; AbGenomics International; AbGenomics International
Travel, Accommodations, Expenses - AbGenomics International; AbGenomics International; AbGenomics International; AbGenomics International
 
Peter J. Langecker
Employment - Clinipace; Clinipace; Clinipace; Clinipace
Leadership - Clinipace; Clinipace; Clinipace; Clinipace
Stock and Other Ownership Interests - Los Gatos Pharmaceuticals; Los Gatos Pharmaceuticals; Los Gatos Pharmaceuticals; Los Gatos Pharmaceuticals
Consulting or Advisory Role - Clinipace; Clinipace; Clinipace; Clinipace
Patents, Royalties, Other Intellectual Property - Los Gatos Pharmaceuticals; Los Gatos Pharmaceuticals; Los Gatos Pharmaceuticals; Los Gatos Pharmaceuticals
Travel, Accommodations, Expenses - Clinipace; Clinipace; Clinipace; Clinipace
 
Shih-Yao Lin
Employment - AbGenomics International; AbGenomics International; AbGenomics International; AbGenomics International
Leadership - AbGenomics International; AbGenomics International; AbGenomics International; AbGenomics International
Stock and Other Ownership Interests - AbGenomics International; AbGenomics International; AbGenomics International; AbGenomics International
Patents, Royalties, Other Intellectual Property - AbGenomics International; AbGenomics International; AbGenomics International; AbGenomics International